Mannkind Corp (MNKD) Stock Price, Quote & News

Company Profile

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of therapeutic products and services for endocrine and orphan lung diseases in the United States. It offers Afrezza Inhalation Powder, an inhaled insulin used to improve glycemic control in adults with diabetes; the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults; and Tyvaso DPI for the treatment of pulmonary arterial hypertension and pul...

Industry: Biotechnology

Sector: Healthcare

Phone: 818 661 5000

Website: www.mannkindcorp.com

Address:

1 Casper Street, Danbury, United States

MoneyGroupLLC Oct. 25 at 4:31 PM

Enter: $MNKD Calls Strike Price: $6 Expiry Date: NOV 14 2025 Buy in Price: $0.20 - $0.50 Sell Price: $0.28 Profit : +41% (Turn every $1 into $1.41) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us/

0 · Reply

NatesNotes Oct. 25 at 3:27 PM

SCAM ALERT - though I have already made one post about it, just a heads up to everyone on the stream that the fraudulent account that is attempting to look like mine (same screen name, but no "s" after "Nate") is now apparently also soliciting people to open and fund trading accounts "in order to follow Nate Pile's trades" (or similar); however, please note that it is a SCAM, and rather than opening an account, you should instead report the fraudulent account to ST (click on the three dots associated with that profile and then click "report"). I have sent a message to ST and one of its founders in hopes they will remove the account before anyone gets hurt, but if you could all report @NateNotes as well, it would likely help accelerate the process. Thanks in advance (and, of course, Go $MNKD! :-) ).

1 · Reply

kevinmik Oct. 25 at 3:17 PM

$MNKD Here are the choices facing Mannkind Board of Directors for the future direction of the company to best unlock value for shareholders. The status quo cannot continue and to meet their fiduciary responsibility Mannkind Board of Directors must start doing what's in the best interest of their sareholders. They cannot continue to allow Mannkind Executives to enrich themselves year after year approving undeserved compenstion packages and focus on shareholder value. 1) Sell Mannkind 2) Merge Mannkind With United Therapeutic 3) Restructure Mannkind Spinning Out A New Company 4) Sell Tyvaso DPI Asset To United Therapeutic To Focus Mannkind Other Assets 5) Sign New Partnership Deals 6) Have United Therapeutic or Another Pharma Company Take Equity Stake In Mannkind 7) Expand Mannkind Innovative Inhaled Drug Delivery Platform To Include Multiple Diseases & Disorders 8) Hold Management & CEO Accountable For Growing Shareholder Value, Stock Price & Market Cap 9) Hire New CEO

1 · Reply

kevinmik Oct. 25 at 1:59 PM

$MNKD Furoscix and Furoscx ReadyFlow Autoinjector still MIA from Mannkind website. This should have been ready to go as soon the acquisition deal closed that happened on October 7, 2025.

1 · Reply

beerm Oct. 25 at 5:21 AM

$MNKD Looks like BP is using hedge funds to increase the short position. I can smell the fears coming from BP.

1 · Reply

Kool_Aid_Mann Oct. 25 at 3:14 AM

$MNKD While all of the indices are setting record highs, MNKD is down 20% for the year, what's new? Down 66% on 10 years, down 90%+ for all time.

1 · Reply

kevinmik Oct. 25 at 2:50 AM

$MNKD Things kick off next Wednesday October 29th, when United Therapeutic releases their 3Q 2025 earnings report and then Mannkind is presenting Inhale-1 full study including safety extension results the next week on Wednesday November 5th and release 3Q Earnings results with host conference call the following day on Thursday November 6th. Mannkind could also release other catalyst updates over the next 2 week. Will be interesting to see where the stock price is trading 2 weeks from today on November 7th. Will it remain stuck in the $5 range or will it finally break above $6, $7 or higher.

2 · Reply

NatesNotes Oct. 24 at 11:46 PM

$MNKD Love it! After getting burned so badly last time around, it will interesting to see how how much money they're willing to lose on this go 'round before they finally throw in the towel again – you'd think they would have learned their lesson by now! Either way - more fun and excitement (and profits!) for the rest of to look forward to, eh? ;-) As always, thanks for sharing, SLA! Cheers! #knowwhatyouown #factsmatter

2 · Reply

Golf365 Oct. 24 at 11:07 PM

$MNKD In 2 weeks time we gained 7 million more short shares. Now at 25 million short. Mike, please leave and take the BOD with ya.

0 · Reply

MrSpeaker Oct. 24 at 11:03 PM

$MNKD The_Owl_ What is your take on 7,000,000 +- shares short Mnkd ? Should we be surprised ?

1 · Reply

MannKind: Durable Cash Engine, Optional Catalysts Pending

Oct 13, 2025, 8:05 AM EDT - 12 days ago

MannKind Announces U.S. FDA Accepts for Review its Supplemental Biologics License Application (sBLA) for Inhaled Insulin (Afrezza) in Children and Adolescents Aged 4-17 Years Living with Diabetes

Oct 7, 2025, 9:02 AM EDT - 18 days ago

MannKind Completes Acquisition of scPharmaceuticals, Accelerating Revenue Growth in Cardiometabolic Care

Sep 29, 2025, 6:05 AM EDT - 26 days ago

MannKind Appoints Dr. Ajay Ahuja as Executive Vice President and Chief Medical Officer

Sep 16, 2025, 12:17 PM EDT - 5 weeks ago

SCPHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of scPharmaceuticals Inc. - SCPH

SCPH

Sep 10, 2025, 7:30 PM EDT - 6 weeks ago

MannKind Corporation (MNKD) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 7, 2025, 9:55 PM EDT - 6 weeks ago

MannKind Corporation (MNKD) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript

Sep 7, 2025, 9:28 PM EDT - 6 weeks ago

MannKind Corporation (MNKD) Presents At Cantor Global Healthcare Conference 2025 Transcript

Aug 27, 2025, 4:05 PM EDT - 2 months ago

MannKind to Present at Upcoming Investor Conferences

Aug 27, 2025, 8:05 AM EDT - 2 months ago

MannKind Announces Expansion of United Therapeutics Collaboration for Second Inhaled Therapy

Aug 25, 2025, 1:57 PM EDT - 2 months ago

MannKind, Backed By Blackstone, Expands Cardiorenal Focus With $360 Million Deal

Aug 25, 2025, 1:36 PM EDT - 2 months ago

MannKind Corporation (MNKD) Mergers and Acquisition Call Transcript

Aug 6, 2025, 5:20 PM EDT - 2 months ago

MannKind Corporation (MNKD) Q2 2025 Earnings Conference Call Transcript

Aug 6, 2025, 4:44 PM EDT - 2 months ago

MannKind Corporation: A Post-Q2 Assessment

Aug 6, 2025, 7:10 AM EDT - 2 months ago

MannKind and Blackstone Announce up to $500 Million Strategic Financing Agreement

Aug 6, 2025, 7:05 AM EDT - 2 months ago

MannKind Corporation Reports Second Quarter 2025 Financial Results And Provides Business Update

Jul 30, 2025, 4:05 PM EDT - 3 months ago

MannKind Corporation to Hold 2025 Second Quarter Financial Results Conference Call on August 6, 2025

Jun 11, 2025, 7:01 AM EDT - 4 months ago

Top 3 Health Care Stocks That May Rocket Higher This Quarter

Jun 9, 2025, 4:05 PM EDT - 4 months ago

MannKind to Highlight Data from Recent Pediatric and Adult Studies of Inhaled Insulin (Afrezza®) at American Diabetes Association's 85th Scientific Sessions in Chicago, June 20-23

May 27, 2025, 9:15 AM EDT - 5 months ago

INDYCAR Driver Conor Daly To Share His Personal Diabetes Story and Race Go-Karts With Detroit Area Youth On Thursday, May 29

May 27, 2025, 12:02 AM EDT - 5 months ago

MannKind: Why I'm Still Bullish Despite Tyvaso DPI Competition

May 8, 2025, 11:34 AM EDT - 6 months ago

MannKind Corporation (MNKD) Q1 2025 Earnings Call Transcript

May 8, 2025, 8:05 AM EDT - 6 months ago

MannKind Corporation Reports First Quarter 2025 Financial Results and Provides Business Update

May 1, 2025, 4:05 PM EDT - 6 months ago

MannKind Corporation to Hold 2025 First Quarter Financial Results Conference Call on May 8, 2025

Apr 7, 2025, 12:30 PM EDT - 7 months ago

MannKind Teams Up with Juncos Hollinger Racing (JHR) Driver Conor Daly to Drive Awareness of Diabetes and Innovative Treatment Options

Mar 10, 2025, 6:05 AM EDT - 8 months ago

MannKind Showcases Efficacy, Safety, and Mealtime Control Data from Recent Pediatric and Adult Studies of Afrezza® at the ATTD Conference, March 19-22

Feb 27, 2025, 10:32 AM EST - 8 months ago

MannKind Q4 Review: Solid Financials, But Tyvaso DPI's Market Share In Question

Feb 26, 2025, 9:09 PM EST - 8 months ago

MannKind Corporation (MNKD) Q4 2024 Earnings Call Transcript

Feb 26, 2025, 4:05 PM EST - 8 months ago

MannKind Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Feb 19, 2025, 4:05 PM EST - 8 months ago

MannKind Corporation to Hold 2024 Fourth Quarter and Full Year Financial Results Conference Call on February 26, 2025

Feb 3, 2025, 9:20 AM EST - 9 months ago

MoneyShow's Best Investment Ideas For 2025: Part 8

DELL FNV MSTR SKE SKYE AMSC

Jan 6, 2025, 4:30 PM EST - 10 months ago

MannKind Expands Executive Leadership Team

Dec 17, 2024, 7:16 AM EST - 11 months ago

MannKind Corporation: A Speculative Buy On IPF And Diabetes Markets

Dec 16, 2024, 6:05 AM EST - 11 months ago

MannKind Announces Six-Month Results From Phase 3 INHALE-1 Pediatric Diabetes Trial Utilizing Inhaled Insulin (Afrezza®)

Dec 11, 2024, 6:00 AM EST - 11 months ago

CDSCO Approves Afrezza® (insulin human) Inhalation Powder in India

Nov 7, 2024, 8:30 PM EST - 1 year ago

MannKind Corporation (MNKD) Q3 2024 Earnings Conference Call Transcript

Nov 7, 2024, 4:02 PM EST - 1 year ago

MannKind Corporation Reports 2024 Third Quarter Financial Results and Provides Business Update

Nov 5, 2024, 4:15 PM EST - 1 year ago

MannKind to Present at 2024 UBS Healthcare Conference

Nov 4, 2024, 6:05 AM EST - 1 year ago

MannKind Successfully Completes Phase 1 Trial of Nintedanib DPI for Pulmonary Fibrotic Diseases

Oct 31, 2024, 4:05 PM EDT - 1 year ago

MannKind Corporation to Hold 2024 Third Quarter Financial Results Conference Call on November 7, 2024

Oct 30, 2024, 9:00 PM EDT - 1 year ago

First Site Initiated in Australia for MannKind's Phase 3 Clinical Trial Evaluating Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease

Oct 3, 2024, 8:00 AM EDT - 1 year ago

MannKind Leverages Tyvaso DPI Strength In Pulmonary Market Expansion

Sep 30, 2024, 6:00 AM EDT - 1 year ago

More Adults With Type 1 Diabetes Achieved A1C Goal (

Sep 18, 2024, 6:15 AM EDT - 1 year ago

MannKind Announces Clearance from PMDA to Initiate Phase 3 Clinical Trial (ICoN-1) in Japan Evaluating Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease

Sep 10, 2024, 4:30 PM EDT - 1 year ago

MannKind to Present at 2024 Cantor Fitzgerald Global Healthcare Conference

Aug 27, 2024, 4:30 PM EDT - 1 year ago

MannKind to Present at Upcoming Conferences

Aug 14, 2024, 8:00 AM EDT - 1 year ago

Kent Kresa to Retire from MannKind's Board of Directors; Steven B. Binder to be Appointed to the Board

Aug 7, 2024, 12:29 PM EDT - 1 year ago

MannKind Corporation (MNKD) Q2 2024 Earnings Call Transcript

Aug 7, 2024, 8:00 AM EDT - 1 year ago

MannKind Corporation Reports 2024 Second Quarter Financial Results: Provides Clinical Development Update

Jul 31, 2024, 6:30 AM EDT - 1 year ago

MannKind Launches Educational Website to Raise Awareness of NTM Lung Disease

MoneyGroupLLC Oct. 25 at 4:31 PM

0 · Reply

NatesNotes Oct. 25 at 3:27 PM

1 · Reply

kevinmik Oct. 25 at 3:17 PM

1 · Reply

kevinmik Oct. 25 at 1:59 PM

$MNKD Furoscix and Furoscx ReadyFlow Autoinjector still MIA from Mannkind website. This should have been ready to go as soon the acquisition deal closed that happened on October 7, 2025.

1 · Reply

beerm Oct. 25 at 5:21 AM

$MNKD Looks like BP is using hedge funds to increase the short position. I can smell the fears coming from BP.

1 · Reply

Kool_Aid_Mann Oct. 25 at 3:14 AM

$MNKD While all of the indices are setting record highs, MNKD is down 20% for the year, what's new? Down 66% on 10 years, down 90%+ for all time.

1 · Reply

kevinmik Oct. 25 at 2:50 AM

2 · Reply

NatesNotes Oct. 24 at 11:46 PM

2 · Reply

Golf365 Oct. 24 at 11:07 PM

$MNKD In 2 weeks time we gained 7 million more short shares. Now at 25 million short. Mike, please leave and take the BOD with ya.

0 · Reply

MrSpeaker Oct. 24 at 11:03 PM

$MNKD The_Owl_ What is your take on 7,000,000 +- shares short Mnkd ? Should we be surprised ?

1 · Reply

MrSpeaker Oct. 24 at 10:55 PM

$MNKD ✅

0 · Reply

rooksleanne Oct. 24 at 10:21 PM

$MNKD Scripts Friday

1 · Reply

YolitheDolly Oct. 24 at 10:12 PM

$MNKD As usual, this pos wipes out all the gains I made today in my other investments. Thanks Mike!

0 · Reply

Pickin Oct. 24 at 9:06 PM

$MNKD another stellar weekly performance of mediocrity

1 · Reply

HumphreyB Oct. 24 at 9:04 PM

$MNKD Market is flaming hot, this is also a flaming you know what

0 · Reply

clan Oct. 24 at 9:02 PM

$MNKD Afrezza Jake, racecar driver Conor Daly, super heroin StarGirl, LEO Timothy Brown, and .... King Trump. All users of Afrezza.

1 · Reply

sla55 Oct. 24 at 8:59 PM

$MNKD Short Interest 10/15/25: 25,157,617 (SP: $5.23) Days to cover: 5.18452 Short Interest 9/30/25: 18,311,133 (SP: $5.37) Change: 6,846,484

4 · Reply

Golf365 Oct. 24 at 8:46 PM

$MNKD This is a total slap in shareholders faces. Anyone who approves of Castagna is a flaming moron.

1 · Reply

HumphreyB Oct. 24 at 8:41 PM

$MNKD Guys, be careful there's a fake @zmanx, posting as @zmanx1, @zmanx11, trying to convince people to use "tradeechocapital", which is a scam site. @MayorofMNKD I see you follow him, make sure to report and do not listen to him.

0 · Reply

firefox2778 Oct. 24 at 8:30 PM

$MNKD I remember talking with you about Nokia and you told me that was a chitty company (and it is). Well, today sold my LT position of more than 25k shares built around $3.10-3.15 when stock was awful. Imagine that, I was able to make money with Nokia (a miracle), probably, I’ll have a chance to make money here too. Thanks Gosh my position in Magnificent 7 is doing extraordinary (started to sell some too because run is too long to last) and probably MNKD is next? Hope so for everyone

1 · Reply

Hard2beLong Oct. 24 at 8:25 PM

$MNKD I have to admit that in one thing this stock is unique. In 14 years it has been always a roller coaster, always. Still waiting for my double digits and for embarrassment of riches

0 · Reply

santinov Oct. 24 at 8:24 PM

$MNKD The Clanster quoted/pumped Oppenheimers $15 projection for MNKD. I actually think that those might be the Clan's IQ...... Now he's moved on to Cipla and India without even realizing that the average annual Income in India is US. 2,400. ( AVG income for USA 67,000 or 28X that of India ) Average weekly scripts for USA are between 850 and 900 in America where citizens earn 28 times the income of Indians...... Cows are sacred in India but it is unlikely, considering the economics, that Afrezza will become a cash cow. The Clanster has never let reality intercede in his passionate pumping of mike. I think they both get their jollies from it. Otherwise our resident cherry picking Clanster should reflect on these real numbers MNKD 1 day... down 3.28% 5 days..down 2.93% 1 month down .38% Red for the day, week and month! It's time for $15.OO IQ pumpster Clan to push the Cipla cash cow in india where it's citizens earn 2,400 annually. Dementia reigns!

1 · Reply

Market Cap	1.68B
Revenue (ttm)	285.50M
Net Income (ttm)	27.59M
EPS (ttm)	N/A
PE Ratio	50.27
Forward PE	85.08
Profit Margin	9.66%
Debt to Equity Ratio	-2.54

Volume	2,975,500
Avg Vol	4,890,168
Day's Range	N/A - N/A
Shares Out	306.83M
Stochastic %K	48%
Beta	1.08
Analysts	Strong Sell
Price Target	$10.38